Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Lee CA, Ramaiya A, Tang Y, Sapone A, Gilder K, Randle A, Grundy JS October 11, 2022 UEGW 2022 Ulcerative Colitis

A Phase 1 Drug Interaction Study Evaluating the Effects of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of Etrasimod in Healthy Volunteers

View Presentation
Poster
Danese S, Komori HK, Ryan RD, Cataldi F, Lee CA, Goetsch M, Siegmund B October 11, 2022 UEGW 2022 Ulcerative Colitis

Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

View Presentation
Poster
Feagan BG, * Peyrin-Biroulet L, * Sandborn WJ, D’Haens G, Panés J, Yarur A, Wolf DC, Ritter T, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Baert F, Sands BE, Dubinsky MC, Vermeire S, Goetsch M, Danese S. October 11, 2022 UEGW 2022 Ulcerative Colitis

Etrasimod 2 mg Once Daily as Treatment for Biologic/Janus Kinas Inhibitor-Naive and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

View Presentation
Oral Presentation
Sandborn WJ*, Vermiere S*, Peyrin-Biroulet L, Dubinsky MC, Panés J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D’Haens G, Danese S, Goetsch M, Feagan BG *Co first authors. October 11, 2022 UEGW 2022 Ulcerative Colitis

Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colotis: Results from the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

View Presentation
Poster
Schreiber S, Rubin DT, Ng SC, Modesto I, Guo X, Su C, Kwok KK, Jo H, Chen Y, Yndestad A, Reinisch W, Dubinsky MC October 11, 2022 UEGW 2022 Ulcerative Colitis

Major adverse cardiovascular events by baseline cardiovascular risk stratification in patients with ulcerative colitis treated with tofacitinib: data from the OCTAVE clinical programme

View Presentation
Poster
Lee CA, Waterhouse T, Heathman M, Oh DA, Komori HK, Grundy JS October 11, 2022 UEGW 2022 Ulcerative Colitis

Model-Predicted Lymphocyte Response and Recovery Profiles for the Sphingosine 1-Phosphate Receptor Modulators Ozanimod and Etrasimod

View Presentation
Poster
Lee CA, Tang Y, Villa-Caballero L, Shan K, Randle A, Grundy JS October 11, 2022 UEGW 2022 Ulcerative Colitis

Pharmacokinetics, Safety, and Tolerability of Etrasimod: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Volunteers

View Presentation
Poster
Rubin DT, Salese L, Kotze PG, Woolcott JC, Su C, Mundayat R, Paulissen J, Torres J, Long MD Pfizer owner: Cohen M October 11, 2022 UEGW 2022 Ulcerative Colitis

Presence of risk factors associated with colectomy among patients with colectomy in the tofacitinib OCTAVE ulcerative colitis clinical programme

View Presentation
Poster
Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J October 11, 2022 UEGW 2022 Ulcerative Colitis

Relationship between disease activity as assessed by the Mayo score and work productivity in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction and maintenance studies

View Presentation
Poster
Targownik L, Dubinsky MC, Steinwurz F, Bushmakin AG, Cappelleri JC, Tai E, Gardiner S, Hur P, Panés J October 11, 2022 UEGW 2022 Ulcerative Colitis

Relationship between health-related quality of life and work productivity in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction and maintenance studies

View Presentation